ROLE OF STRESS IN GUT IMMUNE INTERACTIONS WITH COMMENSAL BACTERIA

压力在肠道免疫与共生细菌相互作用中的作用

基本信息

  • 批准号:
    10204715
  • 负责人:
  • 金额:
    $ 64.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-07-18 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Stress is a trigger for flares of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Patients with IBD, and at least a subset of patients with IBS, also have alterations in the gut microbiota (aka dysbiosis) and alterations in the gut immune responses. While studies have demonstrated that immune responses can have effects on GI motility and symptoms, a major gap in our understanding of stress as a trigger for IBD and IBS flares is how, and if, stress is causal in dysbiosis and in alterations in gut immune responses and if these changes contribute to symptoms. We discovered that patients with diarrhea predominant IBS (IBSd) had dysbiosis on 16S rDNA sequencing of feces and increased binding of secretory IgA to fecal bacteria, indicating that IBSd patients had increased antigen specific immune responses to their gut bacteria. Using a mouse model, we found that stress likewise induced diarrhea, visceral hypersensitivity, dysbiosis and increased IgA binding to gut bacteria, recapitulating our findings in human IBSd patients. Notably the GI symptoms following stress were dependent upon the microbiota as germ free mice did not develop diarrhea following stress. Further, fecal microbiota transplantation (FMT) of microbiota from stressed, but not control, mice recapitulated the immunologic features of stress. Moreover, we observed that stress-induced dysbiosis allows the translocation of commensal bacteria to the mesenteric lymph node (MLN) facilitated by the formation of colonic goblet cell associated passages (GAPs), a pathway also known to deliver luminal antigens to antigen presenting cells (APCs) in the lamina propria (LP) for the induction of T cell responses in the MLN. However, which bacteria the immune system is responding to during stress and whether this immune response contributes to dysbiosis and symptoms remains a significant gap in our understanding of stress as a trigger for flares of IBD and IBS. We hypothesize that dysbiosis of the gut microbiota following stress allows for the translocation and adaptive immune responses to specific bacterial taxa which serves to perpetuate dysbiosis and contribute to stress induced GI symptoms. To pursue this hypothesis, we propose the following specific aims: Aim 1. Define the taxa and pathways involved in bacterial translocation (BT) following stress, and how that relates to the changes in the luminal microbiota. Aim 2. Define the gut bacterial antigen specific immune response to stress induced dysbiosis and BT Aim 3. Define the requirement of immune responses to commensal bacteria and the loss of gut bacterial taxa following stress in inducing and maintaining dysbiosis and GI symptoms
应激是肠易激综合征(IBS)和炎症性肠病(IBD)发作的触发因素。患者 IBD患者和至少一部分IBS患者的肠道微生物群也发生了变化(也称为生态失调) 以及肠道免疫反应的改变。虽然研究表明免疫反应可以 对胃肠道动力和症状有影响,这是我们对压力作为IBD触发因素的理解中的一个主要空白 和IBS爆发是如何,如果,压力是导致生态失调和肠道免疫反应改变的原因 以及这些变化是否会导致症状 我们发现腹泻型IBS(IBSd)患者在16S rDNA测序中存在微生态失调, 粪便中分泌型伊加与粪便细菌的结合增加,表明IBSd患者增加了 抗原特异性免疫反应。使用小鼠模型,我们发现压力同样 诱导的腹泻、内脏高敏感性、生态失调和伊加与肠道细菌结合增加, 我们在IBSd患者中的发现。值得注意的是,应激后的胃肠道症状取决于 无菌小鼠在应激后没有发生腹泻。此外,粪便微生物群 来自应激小鼠而非对照小鼠的微生物群的移植(FMT)概括了免疫学特征 压力此外,我们观察到,压力诱导的生态失调允许植物生长素的移位, 细菌向肠系膜淋巴结(MLN)转移促进了结肠杯状细胞的形成 通道(GAP),一种也已知将管腔抗原递送至细胞中的抗原呈递细胞(APC)的途径。 固有层(LP)用于在MLN中诱导T细胞应答。然而,哪些细菌免疫 以及这种免疫反应是否会导致生态失调, 症状仍然是一个显着的差距,我们的理解压力作为一个触发器突发炎症性肠病, IBS.我们假设应激后肠道微生物群的生态失调允许易位, 对特定细菌分类群的适应性免疫应答,其用于使生态失调永久化并有助于 压力引起的胃肠道症状。为了实现这一假设,我们提出以下具体目标: 目标1。定义压力后细菌易位(BT)涉及的分类群和途径,以及如何 这与管腔微生物群的变化有关。 目标2.定义肠道细菌抗原特异性免疫应答对应激诱导的生态失调和BT 目标3.定义对肠道细菌的免疫应答的要求和肠道的损失 应激后诱导和维持生态失调和GI症状的细菌分类群

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHYI S HSIEH其他文献

CHYI S HSIEH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHYI S HSIEH', 18)}}的其他基金

CAR-T cell treatment of CNS Autoimmunity
CAR-T细胞治疗中枢神经系统自身免疫
  • 批准号:
    10641913
  • 财政年份:
    2022
  • 资助金额:
    $ 64.12万
  • 项目类别:
CAR-T cell treatment of CNS Autoimmunity
CAR-T细胞治疗中枢神经系统自身免疫
  • 批准号:
    10539779
  • 财政年份:
    2022
  • 资助金额:
    $ 64.12万
  • 项目类别:
B cell-targeted CAR-T treatment of CNS Autoimmunity
B细胞靶向CAR-T治疗中枢神经系统自身免疫
  • 批准号:
    10514950
  • 财政年份:
    2022
  • 资助金额:
    $ 64.12万
  • 项目类别:
Immune interactions with commensal microbes in early life
生命早期与共生微生物的免疫相互作用
  • 批准号:
    10567936
  • 财政年份:
    2022
  • 资助金额:
    $ 64.12万
  • 项目类别:
B cell-targeted CAR-T treatment of CNS Autoimmunity
B细胞靶向CAR-T治疗中枢神经系统自身免疫
  • 批准号:
    10677698
  • 财政年份:
    2022
  • 资助金额:
    $ 64.12万
  • 项目类别:
Gut Intrinsic Inflammatory Responses
肠道内在炎症反应
  • 批准号:
    10614624
  • 财政年份:
    2021
  • 资助金额:
    $ 64.12万
  • 项目类别:
Gut Intrinsic Inflammatory Responses
肠道内在炎症反应
  • 批准号:
    10456984
  • 财政年份:
    2021
  • 资助金额:
    $ 64.12万
  • 项目类别:
Gut Intrinsic Inflammatory Responses
肠道内在炎症反应
  • 批准号:
    10282913
  • 财政年份:
    2021
  • 资助金额:
    $ 64.12万
  • 项目类别:
The Role of Route of Entry by Bacterial Antigens on Colonic T Cell Responses
细菌抗原进入途径对结肠 T 细胞反应的作用
  • 批准号:
    9912712
  • 财政年份:
    2018
  • 资助金额:
    $ 64.12万
  • 项目类别:
The Role of Route of Entry by Bacterial Antigens on Colonic T Cell Responses
细菌抗原进入途径对结肠 T 细胞反应的作用
  • 批准号:
    10396536
  • 财政年份:
    2018
  • 资助金额:
    $ 64.12万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.12万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 64.12万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 64.12万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 64.12万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 64.12万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 64.12万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 64.12万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 64.12万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 64.12万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 64.12万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了